

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	"20060135578".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/11 10:25
L2	122795	"548"/("215" or "225" or "233" or "235" or "243" or "245" or "247"). ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/11 10:26
L3	312157	"514"/("374" or "376" or "377" or "378" or "380").ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/11 10:26
L4	391245	I2 or I3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/11 10:26
L5	32189	oxazole	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/11 10:26
L6	42653	pyrazole	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/11 10:27
L7	875169	phenyl or benzene	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/11 10:27

## EAST Search History

L8	4588	I4 and I5 and I6 and I7	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/11 10:27
----	------	-------------------------	--	----	----	------------------

Q= A/Ky1

=> d his

(FILE 'HOME' ENTERED AT 09:01:37 ON 11 DEC 2007)

FILE 'REGISTRY' ENTERED AT 09:01:43 ON 11 DEC 2007

L1 620464 S N2C3/ES  
L2 276055 S NCOC2/ES  
L3 208064 S NOC3/ES  
L4 7768 S L1 AND (L2 OR L3)  
L5 STRUCTURE UPLOADED  
L6 29 S L5 SAM SUB=L4  
L7 561 S L5 SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 09:02:42 ON 11 DEC 2007

L8 16 S L7  
L9 2 S US200!-527426/APPS  
L10 1 S L8 AND L9  
L11 15 S L8 NOT L9

FILE 'REGISTRY' ENTERED AT 09:03:09 ON 11 DEC 2007









=> d l5

L5 HAS NO ANSWERS

L5 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.



chain nodes :

1 3 4 8 9 13 14 15 16 17 21 22 23 28

chain bonds :

1-3 3-4 4-8 8-9 9-28 13-16 14-17 14-22 15-23 16-21

exact/norm bonds :

1-3 3-4 4-8 8-9 9-28 13-16 14-17 14-22 15-23 16-21

G1: [\*1], [\*2], [\*3]

Connectivity :

4:2 E exact RC ring/chain 13:2 E exact RC ring/chain 14:2 E exact RC ring/chain  
15:2 E exact RC ring/chain

Match level :

1:Atom 3:CLASS 4:CLASS 8:CLASS 9:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS  
17:CLASS 21:Atom 22:Atom 23:Atom 28:CLASS

Generic attributes :

1:  
Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Monocyclic

9:  
Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic

21:

Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Monocyclic

22:

Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Monocyclic

23:

Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Monocyclic

Element Count :

Node 1: Limited

C,C3

O,O1

N,N1

Node 9: Limited

C,C6

Node 21: Limited

C,C3

N,N2

Node 22: Limited

C,C3

N,N2

Node 23: Limited

C,C3

N,N2

FILE 'HOME' ENTERED AT 09:01:37 ON 11 DEC 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:01:43 ON 11 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 DEC 2007 HIGHEST RN 957336-90-2

DICTIONARY FILE UPDATES: 10 DEC 2007 HIGHEST RN 957336-90-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s n2c3/es

L1 620464 N2C3/ES

=> s ncoc2/es

L2 276055 NCOC2/ES

=> s noc3/es

L3 208064 NOC3/ES

=> s l1 and (l2 or l3)

L4 7768 L1 AND (L2 OR L3)

=>

Uploading C:\Program Files\Stnexp\Queries\11527426-update.str



chain nodes :  
 1 3 4 8 9 13 14 15 16 17 21 22 23 28  
 chain bonds :  
 1-3 3-4 4-8 8-9 9-28 13-16 14-17 14-22 15-23 16-21  
 exact/norm bonds :  
 1-3 3-4 4-8 8-9 9-28 13-16 14-17 14-22 15-23 16-21

G1: [\*1], [\*2], [\*3]

Connectivity :  
 4:2 E exact RC ring/chain 13:2 E exact RC ring/chain 14:2 E exact RC ring/chain  
 15:2 E exact RC ring/chain  
 Match level :  
 1:Atom 3:CLASS 4:CLASS 8:CLASS 9:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS  
 17:CLASS 21:Atom 22:Atom 23:Atom 28:CLASS  
 Generic attributes :  
 1:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : 2 or more  
 Type of Ring System : Monocyclic  
 9:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Type of Ring System : Monocyclic  
 21:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : 2 or more  
 Type of Ring System : Monocyclic  
 22:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : 2 or more  
 Type of Ring System : Monocyclic  
 23:  
 Saturation : Unsaturated

Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Monocyclic

Element Count :  
Node 1: Limited  
C,C3  
O,O1  
N,N1

Node 9: Limited  
C,C6

Node 21: Limited  
C,C3  
N,N2

Node 22: Limited  
C,C3  
N,N2


Node 23: Limited  
C,C3  
N,N2

L5        STRUCTURE UPLOADED



L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:252494 CAPLUS  
 DN 140:287404  
 TI Preparation of five-membered heterocyclic compounds for treatment of obesity, diabetes, hyperlipidemia, etc.  
 IN Momose, Yu; Takakura, Nobuyuki; Maekawa, Tsuyoshi; Odaka, Hiroyuki; Kimura, Hiroyuki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 442 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024705	A1	20040325	WO 2003-JP11511	20030909
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004123732	A	20040422	JP 2003-316475	20030909
	AU 2003262023	A1	20040430	AU 2003-262023	20030909
	EP 1541564	A1	20050615	EP 2003-795338	20030909
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006135578	A1	20060622	US 2005-527426	20050310 <--
PRAI	JP 2002-264703	A	20020910		
	WO 2003-JP11511	W	20030909		
OS	MARPAT 140:287404				
GI					



I

AB The title compds. I [R1 is a group derived from an optionally substituted five-membered heterocycle; X, Y and V are each independently oxygen, sulfur, or the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; A is an aromatic ring which may have one to three addnl. substituents; Z is (CH2)<sub>n</sub>Z1 or Z1(CH2)<sub>n</sub> (wherein n is an integer of 0 to 8 and Z1 is oxygen, sulfur, or the like); B is a nitrogenous heterocycle which may have one to three addnl. substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; and R2 is hydrogen, cyano, PO(OR9)(OR10) (wherein R9 and R10 are each independently hydrogen or optionally substituted hydrocarbyl, or R9 and R10 may be united to form an optionally substituted ring), or the like] are prepared In a binding assay for the human PPAR  $\gamma$ 1 receptors, compds. of this invention showed IC50 values of 7.4 nM to 7300 nM. Formulations are given.

RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN  
 3006.314492 CAPLUS Full-text  
 144:357706  
 TI Modified-release formulations  
 IN Ono, Akihiko; Yoneyama, Shuji  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DT PATENT  
 LA English  
 EAN CNT.1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006036007	A2	20060406	WO 2005-JP18486	20050929
WO 2006036007	A3	20060914		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MU, MV, MW, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG, BM, GH, GM, KE, LS, MG, MN, SD, SL, SZ, TZ, ZM, ZW, AZ, AY				
KG, KZ, MD, RU, TJ, TM				
JP 2006124385	A	20060518	JP 2005-284233	20050929
PRAI JP 2004287244	A	20040930		


OS MARPAT 14.4:357706  
AB The present invention relates to a pharmaceutical agent comprising a 5-membered nitrogen heterocyclic compound is useful as an agent for the prophylaxis or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, and arteriosclerosis. The compound shows improved sustainability of an effect on the blood concentration. Thus, a formulation containing 14-(2-phenyl-4-oxazolinomethoxy)benzyl-1H-pyrazol-4-yl pyrophosphate 48.0, sucrose 36.0, starch 21.2, cellulose 10.7, and low-substituted HPC 12.4 mg.

IT 342026-63-5 342026-78-2 342026-96-4  
342027-06-9  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(modified-release formulations)


RN 342026-63-5 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-78-2 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methyl]- (CA INDEX NAME)



RN 342026-96-4 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)



RN 342027-06-9 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl]methoxy]phenyl]methyl]- (CA INDEX NAME)




✓ 1 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:185213 CAPLUS Full-text

AN 2006:185213 CAPLUS Full-text  
DN 144:390910  
TI Preparation of substituted pyrazolone derivatives and their pharmaceutical compositions

IN Wang, Yalou; Liu, Xing; Liu, Xiaoyan  
PA China Pharmaceutical University, Peop. Rep. China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 21 pp.  
CODEN: CNXXEV


DT	COLDET: CNAAEV			
LA	Patent Chinese			
FAN.CNT 1				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1594316	A	20050316	CN 2004-10041141	20040701
PRAT CN 2004-10041141		20040701		
OS MARPAT 144:350910				
GI				




AB A pyrazolone derivative I having blood sugar lowering action is prepared where R<sub>1</sub> is hydrogen or C1-8 alkyl or alkoxy; R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> are H, halogen, C1-8 alkyl or alkoxy, hydroxy, cyano, methylthio or methylsulfonyl; n = 1-4; L and M are H or a chemical bond.

IT 283309-30-6P 323309-36-2P 583309-48-3P  
 983309-53-3P 083309-51-3P 883309-66-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USBS  
 (Uses)  
 (preparation of substituted pyrazolone derivs. having blood sugar lowering  
 action)

RN 883309-30-6 CAPLUS  
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-2-phenyl- (CA INDEX NAME)




RN 883309-36-2 CAPLUS  
CN 3H-Pyrazol-3-one, 2,4-dihydro-4-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-5-methyl-2-phenyl- (CA INDEX NAME)




RN 883309-45-3 CAPLUS  
CN 3H-Pyrazol-3-one, 4-[[4-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-


3-methoxyphenyl)methyl]-2,4-dihydro-5-methyl-2-phenyl- (CA INDEX NAME)




RN 003309-53-3 CAPLUS  
CN 3H-Pyrazol-3-one, 4-[[4-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methyl]-2,4-dihydro-5-methyl-2-phenyl- (CA INDEX NAME)




RN 883309-61-3 CAPLUS  
CN 3H-Pyrazol-3-one, 4-[[4-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methyl]-2,4-dihydro-5-methyl-2-phenyl- (CA INDEX NAME)



RN 883309-66-8 CAPLUS  
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-4-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-2-phenyl- (CA INDEX NAME)



Double bond geometry as shown.



IT 235501-82-2P 235501-84-3P 235501-85-4P

835901-26-5F 835901-37-EP


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazole derivs. as tyrosine kinase inhibitors for prevention/treatment of cancer in mammals)

RN 835901-83-2 CAPLUS

CN Carbonic acid, ethyl 2-[5-[4-[4-[[2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]-2-methylphenyl]butyl]-1H-pyrazol-1-yl]ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 835901-84-3 CAPLUS

CN Glycine, N,N-dimethyl-, 2-[5-[4-[4-[[2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]-2-methylphenyl]butyl]-1H-pyrazol-1-yl]ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



11527426-update

ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

2005:120041 CAPLUS Full-text

DN 142:191225

TI Oxazole derivatives, pharmaceuticals containing them, inhibition of tyrosine kinase and prevention/treatment of cancer in mammals with them, and use of them in manufacture of tyrosine kinase inhibitors and antitumor agents

IN Taniguchi, Takahiko; Tsumimoto, Saori; Imamura, Shinichi; Yoshida, Kiyoshi

PA Takeda Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 58 pp.

CODEN: JKKXAF


DT Patent

LA Japanese

FAM. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005035935	A	20050210	JP 2003-274921	20030715
JP 2003-274921		20030715		
MARPAT 142:191225				

GI



AB The derivs. I [A = N-heterocycle; B = O, direct bond; R = (un)substituted hydrocarbyl, heterocyclyl; R1 = halo, Cl-4 (halo)alkyl; R2 = H, halo, Cl-4 (halo)alkyl; R3 = H, halo, Cl-3 alkyl, (un)substituted OH; X = O, CH2; Y = O, direct bond; Z = Cl-10 alkylene; W = Cl-4 alkylene; if Z is attached to N atom of ring A, then X = O] or their salts are claimed. I Inhibit tyrosine kinase, especially HER2 kinase, and are useful for prevention and treatment of mammary cancer, prostatic cancer, lung cancer, renal cancer, etc. Thus, 2-[5-[4-[[2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]-2-methylphenyl]butyl]-1H-pyrazol-1-yl]ethyl (dimethylamino)acetate (II; preparation given) inhibited phosphorylation of HER2 expressed by BT-474 human breast cancer cell at IC50 18 nM and also suppressed growth of the cells IC50 0.016 μM. Tablets of II were also formulated.

IT 835901-39-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of oxazole derivs. as tyrosine kinase inhibitors for prevention/treatment of cancer in mammals)


RN 835901-89-8 CAPLUS

CN 1H-Pyrazole-1-ethanol, 5-[4-[2-methyl-4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (CA INDEX NAME)

RN 835901-85-4 CAPLUS

CN Glycine, N,N-dimethyl-, 2-[5-[4-[2-methyl-4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-pyrazol-1-yl]ethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 835901-86-5 CAPLUS

CN Acetic acid, (2-methoxyethoxy)-, 2-[5-[4-[2-methyl-4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-pyrazol-1-yl]ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 835901-87-6 CAPLUS

CN Butanedioic acid, mono[2-[5-[4-[2-methyl-4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-pyrazol-1-yl]ethyl] ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 548595-5a-3P 535901-91-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazole derivs. as tyrosine kinase inhibitors for prevention/treatment of cancer in mammals)

RN 548595-53-9 CAPLUS

CN 1H-Pyrazole-1-ethanol, 5-[4-[4-[[2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (CA INDEX NAME)


Double bond geometry as shown.




RN 835901-91-2 CAPLUS

CN Butanedioic acid, 1,1-dimethylethyl 2-[5-[4-[2-methyl-4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-pyrazol-1-yl]ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




PAGE 1-A



PAGE 1-B


T\* Preparation of azolecarboxylic acids useful as antidiabetic and antioesity agents  
 Chang, Peter T.; Zhang, Hao; Hariharan, Narayanan  
 Bristol-Myers Squibb Company, USA  
 SO U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 153,454.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN. CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003158232	A1	20030821	US 2002-294525	20021114
US 6967212	B2	20051122		
US 2003092736	A1	20030515	US 2002-153454	20020522
US 2005124661	A1	20050609	US 2004-12810	20041215
PRAI US 2001-294380P	P	20010530		
US 2002-153454	A2	20020522		
US 2002-294525	A3	20021114		
OS MARPAT 139:197489				
GI				




AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x20(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; 21 of x2, x3 = 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxy, carbonyl, alkyloxy, carbonyl, alkynyl, carbonyl, alkenyl, carbonyl, aryl, carbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor- $\alpha$  (PPAR $\alpha$ ) and stimulators of peroxisome proliferator activated receptor- $\gamma$  (PPAR $\gamma$ ). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPAR $\alpha$  and to PPAR $\gamma$  ligand binding domains with IC50 = 69 nM.  
 IT 477774-13-3P 477774-17-7P 477774-24-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of azolecarboxylic acids useful as antidiabetic and antioesity agents)  
 RN 477774-54-2 CAPLUS  
 CN 1H-Pyrazole-4-carboxylic acid, 3-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-1-phenyl- (CA INDEX NAME)



RN 477774-55-3 CAPLUS  
 CN 1H-Pyrazole-4-carboxylic acid, 3-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-1-phenyl- (CA INDEX NAME)




RN 477774-56-4 CAPLUS  
 CN 1H-Pyrazole-4-carboxylic acid, 5-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-1-phenyl- (CA INDEX NAME)




RN 477774-57-5 CAPLUS  
 CN 1H-Pyrazole-4-carboxylic acid, 5-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-1-phenyl- (CA INDEX NAME)




(prepn of azolecarboxylic acids useful as antidiabetic and antioesity agents)  
 RN 477774-13-3 CAPLUS  
 CN 1H-Pyrazole-4-carboxylic acid, 3-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 477774-17-7 CAPLUS  
 CN 1H-Pyrazole-4-carboxylic acid, 5-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-1-phenyl-, methyl ester (CA INDEX NAME)




RN 477774-24-6 CAPLUS  
 CN 1H-Pyrazole-3-carboxylic acid, 4-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-1-phenyl-, 2-(5-methyl-2-oxazolyl)ethyl ester (CA INDEX NAME)



IT 477774-54-2P 477774-55-3P 477774-56-4P  
 477774-57-5P 477774-58-6P

RN 477774-58-6 CAPLUS  
 CN 1H-Pyrazole-3-carboxylic acid, 4-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-1-phenyl- (CA INDEX NAME)



RE. CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ 11 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:570981 CAPLUS Full-text  
 DN 139:133571  
 TI Preparation of heterocyclic compounds such as oxazoles as anticancer agents  
 IN Takada, Akihiro; Taniguchi, Takahiko; Takakura, Nobuyuki; Momose, Yu; Naito, Kenichiro; Tsujimoto, Saori  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 274 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003059907	A1	20030724	WO 2003-JP310	20030116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LB, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003203170	A1	20030730	AU 2003-203170	20030116
JP 2003277379	A	20031002	JP 2003-8814	20030116
PRAI JP 2002-9255	A	20020117		
WO 2003-JP310	N	20030116		
OS MARPAT 139:133571				
GI				



AB The title compds. I [A is a nitrogenous heterocycle; B is an optionally substituted aromatic heterocycle or an optionally substituted aromatic heterocycle; C is a 5- or 6-membered nitrogenous heterocycle which may be substituted; R is an optionally substituted aromatic heterocyclic group or the like; m is an integer of 0 to 2; n is an integer of 1 to 5; X is oxygen or the like; and Y and Z may be the same or different from each other and are each a single bond, an oxygen atom, an optionally substituted carbon atom, or the like] are prepared. Compds. of this invention in vitro showed IC50 values of < 0.05  $\mu$ M to 0.2  $\mu$ M against the growth of breast cancer cells BT-474. Formulations containing I are given.

IT 564595-52-PP 564595-52-9P 564595-54-OP  
564595-55-1P 564595-56-2P 564595-57-3P  
564595-58-4P 564595-59-5P 564595-60-6P  
564595-61-7P 564595-62-8P 564595-63-9P  
564595-64-1P 564595-65-2P 564595-66-3P  
564595-67-4P 564595-68-5P 564595-69-6P  
564595-70-7P 564595-71-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. such as oxazole derivs. as anticancer agents)

RN 568595-52-8 CAPLUS

CN Oxazole, 2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-[(4-[(1H-pyrazol-3-yl)butyl]phenoxy)methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-53-9 CAPLUS

CN 1H-Pyrazole-1-ethanol, 5-[4-[(2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl)methoxy]phenyl]butyl]- (CA INDEX NAME)


Double bond geometry as shown.




RN 568595-54-0 CAPLUS

CN Oxazole, 2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-[(4-[(1-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-3-yl)butyl]phenoxy)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A




PAGE 1-B

RN 568595-55-1 CAPLUS

CN Oxazole, 2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-[(4-[(1-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-5-yl)butyl]phenoxy)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




PAGE 1-A

PAGE 1-B

ester (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-58-4 CAPLUS

CN 1H-Pyrazole-1-acetamide, 5-[4-[(2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl)methoxy]phenyl]butyl]-N,N-diethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-59-5 CAPLUS

CN 1H-Pyrazole-1-acetamide, 5-[4-[(2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl)methoxy]phenyl]butyl]-N-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 568595-60-8 CAPLUS

CN Oxazole, 4-[(3-methyl-4-[(1H-pyrazol-3-yl)butyl]phenoxy)methyl]-2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]- (CA INDEX NAME)

RN 568595-57-3 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 5-[4-[(2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl)methoxy]phenyl]butyl]-, ethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-61-9 CAPLUS

CN Oxazole, 2-[(1E)-2-[4-bromo-2-fluorophenyl]ethenyl]-4-[[3-methyl-4-[4-(1H-pyrazol-3-yl)butyl]phenoxy]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-62-0 CAPLUS

CN Oxazole, 2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-[[3-methyl-4-[4-(1H-pyrazol-3-yl)butyl]phenoxy]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 568595-63-1 CAPLUS


CN 1H-Pyrazole-1-acetic acid, 3-[4-[4-[[2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]-2-methylphenyl]butyl]-ethyl ester (CA INDEX NAME)

Double bond geometry as shown.

RN 568595-68-6 CAPLUS

CN Oxazole, 4-[2-[3-methyl-4-[3-(1H-pyrazol-3-yl)propoxy]phenyl]ethenyl]-2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-69-7 CAPLUS

CN Oxazole, 2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-[2-[3-methyl-4-[3-(1H-pyrazol-3-yl)propoxy]phenyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-70-0 CAPLUS

CN Oxazole, 4-[3-methyl-4-[4-(1H-pyrazol-4-yl)butyl]phenoxy]methyl]-2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-71-1 CAPLUS

CN Oxazole, 2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-[[3-methyl-4-[4-(1H-pyrazol-4-yl)butyl]phenoxy]methyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-64-2 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 5-[4-[4-[[2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]-2-methylphenyl]butyl]-ethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-65-3 CAPLUS

CN 1H-Pyrazole-1-ethanol, 5-[4-[4-[[2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]-2-methylphenyl]butyl]-ethyl ester (CA INDEX NAME)



Double bond geometry as shown.



RN 568595-72-2 CAPLUS

CN Oxazole, 4-[3-methyl-4-[4-[1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]butyl]phenoxy]methyl]-2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 568595-73-3 CAPLUS

CN 1H-Pyrazole-1-ethanol, 4-[4-[2-methyl-4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-ethyl ester (CA INDEX NAME)

Double bond geometry as shown.



OH

RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


LI ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:551277 CAPLUS Full-Text  
DN 139:117427  
TI Preparation of 3-(isoxazolyl)propionic acid derivatives as neurotrophic factor production/secretion accelerator  
IN Hazama, Masatoshi; Iwakami, Norihisa; Miyazaki, Takeshi; Sakai, Nozomu; Maekawa, Tsuyoshi; Momose, Yu; Kawamura, Toru  
PA Takeda Chemical Industries, Ltd., Japan  
SO PCT Int. Appl., 282 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057215	A1	20030717	WO 2002-JP13654	20021226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002367426	A1	20030724	AU 2002-367426	20021226
JP 2002261545	A	20030919	JP 2002-375898	20021226
PRAI JP 2001-401380	A	20011228		
WO 2002-JP13654	N	20021226		
OS MARPAT 139:117427				
GI				

AB The title compds. I (wherein R1 and R2 = independently H or (un)substituted cyclyl; Y = a bond or alkylene; Y = OR3; R3 = H, (un)substituted hydrocarbyl, heterocyclyl, or acyl, etc.) and salts and prodrugs thereof are prepared as neurotrophic factor production/secretion accelerator. For example, di-Et 4-aminobenzylphosphonate was reacted with 3-(5-phenyl-4-isoxazolyl)propionic acid (preparation given) in DMF in the presence of dehydrating reagents to afford the amide II (93%). II showed 49% pain feeling increase in rat. Formulations containing I as an active ingredient were also described.

IT 562084-29-5F 562084-29-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of isoxazolylpropionic acid derivs. as neurotrophic factor production/secretion accelerator)

RN 562084-29-5 CAPLUS  
CN 4-isoxazolepropanamide, 5-(3,4-dichlorophenyl)-N-[4-(1H-pyrazol-1-ylmethyl)phenyl]- (CA INDEX NAME)





PAGE 1-A

PAGE 2-A



RN 562084-29-1 CAPLUS  
CN 4-isoxazolepropanamide, 5-(4-fluorophenyl)-N-[4-(1H-pyrazol-1-ylmethyl)phenyl]- (CA INDEX NAME)




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LI ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:396860 CAPLUS Full-Text  
DN 138:385422  
TI Process for production of pyrazole compounds  
IN Tawada, Hiroyuki; Yamashita, Makoto; Ikemoto, Tomomi; Nishiguchi, Ateuko  
PA Takeda Chemical Industries, Ltd., Japan  
SO PCT Int. Appl., 91 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003042193	A1	20030522	WO 2002-JP11781	20021112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2467115	A1	20030522	CA 2002-2467115	20021112
AU 2002344651	A1	20030526	AU 2002-344651	20021112
JP 2003212870	A	20030730	JP 2002-327875	20021112
JP 2003212854	A	20030730	JP 2002-354320	20021112
EP 1445254	A1	20040811	EP 2002-778097	20021112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1630673	A	20050427	CN 2002-826563	20021112
US 2005014813	A1	20050120	US 2004-495173	20040511
PRAI JP 2001-347985	A	20011113		
JP 2002-327875	A3	20021112		
WO 2002-JP11781	N	20021112		
OS CASREACT 138:385422; MARPAT 138:385422				
GI				

GI




AB Provided is a process by which pyrazole compds. useful as intermediates in the preparation of drugs such as diabetes remedies can be easily produced in high yields. Specifically, a process for the production of compds. represented by the general formula (I) or salts thereof (wherein R1 is a hydrocarbon group which may be substituted; and n is an integer of 1 to 4) is characterized by reacting a compound represented by the general formula R2CC(CO)(CH2)nCO2R1 (wherein R2 is optionally substituted hydroxyl or optionally substituted amino; R1 is a hydrocarbon group which may be substituted; and n and R1 are each as defined above) or a salt thereof with hydrazine or a salt thereof. Thus, a mixture of 47.05 g di-Et glutarate and 24.2 mL Et formate was added dropwise to a suspension of 24.5 g sodium tert-butoxide in 300 mL tert-Bu Me ether at 510° under ice-cooling and stirred at room temperature for 24 h to give a reaction mixture containing di-Et 2-formylglutarate which was treated dropwise with 29 mL AcOH and 6.8 mL hydrazine monohydrate at room temperature, refluxed for 2 h with stirring, treated with 120 mL H2O under reflux, cooled to room temperature, and filtered to give, after washing the crystals with H2O and diisopropyl ether, Et 3-(3-hydroxy-1H-pyrazol-4-yl)propionate (III). II (10 g) and 6.25 g K2CO3 were added to 40 mL DMF, treated dropwise with 1.5 mL benzyl chloroformate at 515°, and stirred at room temperature for 1 h to give, after workup, 3-hydroxy-4-(3-ethoxy-3-oxopropyl)-1H-pyrazole-1-carboxylic acid benzyl ester (III'). III' (3.4 g), 2.95 g K2CO3, and 1.11 mL Et iodide were added to 13.6 mL DMF and stirred at 50° for 2 h to give 3-ethoxy-4-(3-ethoxy-3-oxopropyl)-1H-pyrazole-1-carboxylic acid benzyl ester which (0.5 g) was hydrogenolyzed over 0.05 g 10% Pd-C in 5 mL ethanol with vigorous stirring under hydrogen atmospheric to give Et 3-(3-ethoxy-1H-pyrazol-4-yl)propionate (IV). NaH (60%, 96.0 mg) was added to a mixture of 509 mg IV, 753 mg 4-(2-chloromethyl)phenoxyethyl-5-methyl-2-phenylisoxazole, and 10 mL DMF at 0° and stirred at room temperature for 30 min to give, after workup and silica gel chromatography, 3-(3-ethoxy-1-(2-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl)-1H-pyrazol-4-yl)propionic acid Et ester (V). Pharmaceutical formulations, e.g. a tablet containing V, were prepared

IT 342026-63-5f, 3-(3-Ethoxy-1-(4-(5-methyl-2-phenyl-4-oxazolyl)methoxy)benzyl)-1H-pyrazol-4-yl)propionic acid ethyl ester  
342026-77-1P, 3-(3-Ethoxy-1-(4-(2-(2-furyl)-5-methyl-4-oxazolyl)methoxy)benzyl)-1H-pyrazol-4-yl)propionic acid ethyl ester  
342026-83-9P, 3-(3-Ethoxy-1-(3-methoxy-4-(5-methyl-2-phenyl-4-oxazolyl)methoxy)benzyl)-1H-pyrazol-4-yl)propionic acid ethyl ester  
342026-85-1P, 3-(3-Ethoxy-1-(4-(2-(2-furyl)-5-methyl-4-oxazolyl)methoxy)benzyl)-1H-pyrazol-4-yl)propionic acid ethyl ester  
342026-87-1P, 3-(3-Ethoxy-1-(3-methoxy-4-(5-methyl-2-(2-phenyl)-4-oxazolyl)methoxy)benzyl)-1H-pyrazol-4-yl)propionic acid ethyl ester  
342026-96-4P, 3-(3-Ethoxy-1-(4-(2-phenyl-4-oxazolyl)methoxy)benzyl)-1H-pyrazol-4-yl)propionic acid ethyl ester  
342027-16-3P, 3-(3-Ethoxy-1-(2-(5-methyl-2-phenyl-4-oxazolyl)methoxy)benzyl)-1H-pyrazol-4-yl)propionic acid ethyl ester  
342027-10-7f, 3-(3-Ethoxy-1-(3-(5-methyl-2-phenyl-4-oxazolyl)methoxy)benzyl)-1H-pyrazol-4-yl)propionic acid ethyl ester

DOUB: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(antidiabetic agent; production of pyrazole compds. via cyclocondensation of di-Et formylglutarate with hydrazine)


RN 342026-63-5 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-77-1 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-83-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)



RN 342026-85-1 CAPLUS


CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl]methyl]-, ethyl ester (CA INDEX NAME)



IT 342026-64-6P, 3-[3-Ethoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid  
342026-76-2P, 3-[3-Ethoxy-1-[[4-[(2-(2-furyl)-5-methyl-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid  
342026-84-0P, 3-[3-Ethoxy-1-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid  
342026-86-2P, 3-[3-Ethoxy-1-[[4-[(2-(2-furyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxybenzyl]-1H-pyrazol-4-yl]propionic acid  
342026-88-4P, 3-[3-Ethoxy-1-[[3-methoxy-4-[(5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid  
342026-97-5P, 3-[3-Ethoxy-1-[[4-[(2-phenyl-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid  
342027-06-5P, 3-[3-Ethoxy-1-[[4-[(5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid  
342027-17-2P, 3-[3-Ethoxy-1-[[2-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]-1H-pyrazol-4-yl]propionic acid  
342027-19-4P, 3-[3-Ethoxy-1-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid  
342027-21-5P, 3-[3-Ethoxy-1-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid  
R1: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(antidiabetic agent; production of pyrazole compds. via cyclocondensation of di-Et formylglutarate with hydrazine)



RN 342026-64-6 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342026-76-2 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342026-87-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-methoxy-4-[(5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-96-4 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)



RN 342027-18-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342027-20-7 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)


RN 342026-84-0 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342026-86-2 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl]methyl]- (CA INDEX NAME)




RN 342026-88-4 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-methoxy-4-[(5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)



RN 342026-97-5 CAPLUS


CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)






RN 342027-06-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)




RN 342027-17-2 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[(2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)ethyl]- (CA INDEX NAME)




RN 342027-19-4 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[(2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)



RN 342027-21-8 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[(3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)



11527426-update

31 of 93

RE CN 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

RN 2003:154332 CAPLUS Full-text

DN 135:187795

TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E2 (PGE2) receptors

IN Tanil, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 1009 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NO 2003016254	A1	20030227	WO 2002-JP8120	20020808
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, KZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2457468	A1	20030227	CA 2002-2457468	20020808
AU 2002323916	A1	20030303	AU 2002-323916	20020808
EP 1431267	A1	20040623	EP 2002-755874	20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011810	A	20040824	BR 2002-11810	20020808
CN 1551866	A	20041201	CN 2002-817376	20020808
HU 2004001963	A2	20050128	HU 2004-1963	20020808
NZ 531153	A	20050108	NZ 2002-531153	20020808
NZ 541950	A	20070223	NZ 2002-541950	20020808
ZA 2004000973	A	20050104	ZA 2004-973	20040205
NO 200400564	A	20040510	NO 2004-564	20040206
MX 2004PA01253	A	20040603	MX 2004-PA1253	20040209
US 2006258728	A1	20061116	US 2004-486220	20040909
PRAI JP 2001-241867	A	20010809		
WO 2002-JP8120	M	20020808		
OS MARPAT 135:187795				
GI				



AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR3COR10, CH2NR4CONH5SO2R6, CH2SO2NR9COR10, CH2O2CNH5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-


11527426-update

30 of 93

IT 342027-15-1F, 3-[3-Ethoxy-1-[2-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)ethyl]-1H-pyrazol-4-yl]propionic acid ethyl ester  
RL: PAC (Pharmacological activity); RCT (Reactant); SPH (Synthetic preparation); THU (Therapeutic use); BTOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(production of pyrazole compds. via cyclocondensation of di-Et formylglutarate with hydrazine)


RN 342027-16-1 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[2-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)ethyl]-, ethyl ester (CA INDEX NAME)

IT 342027-59-7, 3-[3-Hydroxy-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]-1H-pyrazol-4-yl]propionic acid ethyl ester  
342027-76-0, 3-[1-[4-[(2-(2-Furyl)-5-methyl-4-oxazolyl)methoxy]benzyl]-3-hydroxy-1H-pyrazol-4-yl]propionic acid ethyl esterRL: RCT (Reactant); RACT (Reactant or reagent)  
(production of pyrazole compds. via cyclocondensation of di-Et formylglutarate with hydrazine)


RN 342026-59-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 2,3-dihydro-1-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-2,3-oxo-, ethyl ester (CA INDEX NAME)



RN 342026-76-0 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[(4-[(2-(2-furyl)-5-methyl-4-oxazolyl)methoxy]phenyl)methyl]-2,3-dihydro-3-oxo-, ethyl ester (CA INDEX NAME)



11527426-update

32 of 93

oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic heterocyclyl, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CH2F, CF3, NO2, cyano, Ph, oxo; m, n = 0, 1, 2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2-, C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.) are prepared. These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, benzylpropanamide, 3-oxoisindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzylaminoacetic acid, (pyrazolylmethylphenyl)propionic acid, pyrazolylmethylpropanoic acid, (pyridinylmethylphenyl)propionic acid, phenoxylacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinylmethylphenyl)propanamide, (pyrazolylmethyl)propanamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propanamide, (thiophenylmethylphenyl)propanamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropanamide, (pyrazolylmethylphenyl)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. 1 are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), vasovagal syncope, ejaculation (ejaculation) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucema, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in

the presence of Et<sub>3</sub>N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[(2-(naphthalen-2-yl)ethoxy)-4-(1-pyrazolylmethyl)cinnamic acid Et ester]. 4-[(2-[(2-(naphthalen-1-yl)propanoyl)amino]-4-methylthiomethylphenyl)butanoic acid inhibited the binding of [3H]PGE<sub>2</sub> to prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) receptor subtype EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub>, an EP<sub>4</sub> expressed in CHO cells with K<sub>i</sub> of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation containing (2E)-2-[(2-(naphthalen-2-yl)ethoxy)-4-(1-pyrazolylmethyl)cinnamic acid was described.


IT 49152-87-3P

RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivs. as antagonists of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) receptors as therapeutic agents)

RN 499152-87-3 CAPLUS

CN Benzenepropanamide, N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-2-[(2-(naphthalenyl)ethoxy)-4-(1H-pyrazol-1-yl)methyl]- (CA INDEX NAME)



PAGE 1-A



PAGE 2-A

RE.CMT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LN ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:5954 CAPLUS Full-text  
DN 138:89798

TI Preparation of 4-(phenoxymethyl)-5-methyloxazole derivatives as antidiabetic agents  
IN Momose, Yu; Maekawa, Tsuyoshi; Odaka, Hiroyuki; Kimura, Hiroyuki  
PA Takeda Chemical Industries, Ltd., Japan  
SO PCT Int. Appl., 99 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003000685	A1	20030103	WO 2002-JP6107	20020619
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002315787	A1	20030108	AU 2002-315787	20020619
JP 2003073377	A	20030312	JP 2002-178851	20020619
JP 2001-186952	A	20010620		
WO 2002-JP6107	W	20020619		
OS	MARPAT 138:89798			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [wherein R<sub>1</sub> = (un)substituted (hetero)hydrocarbonyl; X and Y = independently a bond, O, S, CO, CS, SO, SO<sub>2</sub>, CR<sub>3</sub>OR<sub>4</sub>, NR<sub>5</sub>, CONR<sub>6</sub>, or NR<sub>6</sub>CO; R<sub>3</sub> and R<sub>6</sub> = independently H or (un)substituted hydrocarbonyl; R<sub>4</sub> = H or protecting group of OH; R<sub>5</sub> = H, (un)substituted hydrocarbonyl, or protecting group of amino; Q and W = independently (CH<sub>2</sub>)<sub>m</sub>; m = 1-20; ring A = (un)substituted aryl; n = 1-8; ring B = (un)substituted 5-membered ring containing N; V = a bond, O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or NR<sub>7</sub>CO; R<sub>7</sub> = H or (un)substituted hydrocarbonyl; R<sub>2</sub> = PO(OR)<sub>8</sub> (OR<sub>8</sub>), COR<sub>10</sub>, (un)substituted hydrocarbonyl, or heteroaryl; R<sub>8</sub> and R<sub>9</sub> = independently H or (un)substituted hydrocarbonyl; or R<sub>8</sub> and R<sub>9</sub> together form (un)substituted ring; R<sub>10</sub> = H or (un)substituted hydrocarbonyl; with provisos] and salts or prodrugs thereof are prepared as antidiabetic agents. For example, the acid II (prepn given) was treated with iso-Bu chlorocarbonate in THF in the presence of 4-methylmorpholine, followed by the addition of THF solution of H<sub>2</sub>NNH<sub>2</sub>·H<sub>2</sub>O. The above product was then reacted with tri-Me orthobutyrate in 1,4-dioxane in the presence of methanesulfonic acid to afford the target compd III (70%). III showed IC<sub>50</sub> of 0.034 μM and 0.15 μM against peroxisome proliferator-activated receptors (PPAR) γ and PPARγ-RXRα, resp. A capsule formulation containing III as an active ingredient was also described.

IT 479681-84-8P 479681-85-9P 479681-85-1P  
479681-85-2P 479681-87-3P 479681-90-8P  
479681-91-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(diabetes inhibitor; preparation of (phenoxymethyl)methyloxazoles as

antidiabetic agents)

RN 479681-82-8 CAPLUS


CN 1,3,4-Oxadiazole, 2-[(2-[(1-[(4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl)methyl]-3-phenyl-1H-pyrazol-4-yl)ethenyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 479681-83-9 CAPLUS

CN Phosphonic acid, [(1E)-2-[(1-[(4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl)methyl]-3-phenyl-1H-pyrazol-4-yl)ethenyl]-, diethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 479681-85-1 CAPLUS

CN Oxazole, 4-[(4-[(4-[(1E)-2-(2-ethyl-4-thiazolyl)ethenyl]-3-phenyl-1H-pyrazol-1-yl)methyl]-2-methoxyphenoxy)methyl]-2-(2-furanyl)-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 479681-86-2 CAPLUS

CN Oxazole, 4-[(4-[(4-[(1E)-2-(2-ethyl-4-thiazolyl)ethenyl]-3-(2-thienyl)-1H-

pyrazol-1-yl)methyl]phenoxy]methyl]-5-methyl-2-phenyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 479681-87-3 CAPLUS

CN Phosphonic acid, [(1E)-2-[(1-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-3-(2-thienyl)-1H-pyrazol-4-yl)ethenyl]-, diethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 479681-90-8 CAPLUS

CN Oxazole, 4-[(4-[(4-[(1E)-2-(2-ethyl-4-thiazolyl)ethenyl]-3-phenyl-1H-pyrazol-1-yl)methyl]-2-methoxyphenoxy)methyl]-2-(2-furanyl)-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 479681-91-9 CAPLUS

CN Phosphonic acid, [(1E)-2-[(1-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-3-(2-thienyl)-1H-pyrazol-4-yl)ethenyl]-, diethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.






RN 47774-17-7 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-1-phenyl-, methyl ester (CA INDEX NAME)



RN 47774-24-6 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 4-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-1-phenyl-, 2-(5-methyl-2-oxazolyl)ethyl ester (CA INDEX NAME)


IT 47774-54-2P 47774-55-3P 47774-56-4P  
47774-57-5P 47774-58-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 47774-54-2 CAPLUS

oxazolyl)ethoxy]phenyl]methyl)-1-phenyl- (CA INDEX NAME)



L1 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN

RN 2002:849437 CAPLUS Full-text

DN 137:346207

TI ABC expression promoters

IN Sugiyama, Yasuo; Fuse, Hiromitsu; Hirakata, Masao; Tozawa, Ryuichi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002087580	A1	20021107	WO 2002-JP4072	20020424
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RN:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2445322	A1	20021107	CA 2002-3445322	20020424
AU 2002251530	A1	20021111	AU 2002-251530	20020424
JP 2003012551	A	20030115	JP 2002-122349	20020424
EP 1382336	A	20040121	EP 2002-720584	20020424
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004077689	A1	20040422	US 2003-468433	20031016
PRAI JP 2001-128222	A	20010425		
WO 2002-JP4072	W	20020424		

OS MARPAT 137:346207

AB ABC-A1 mRNA expression promoters, LXRα mRNA expression promoters, ABC-G1 mRNA expression promoters, cholesterol transport promoters and cholesterol ester accumulation inhibitors containing PPARδ modulators such as pioglitazone, ABC-G1 mRNA expression promoters containing PPARδ modulators, or ACAT-1 mRNA expression promoters and CEH mRNA expression promoters containing PPARδ modulators such as pioglitazone. These agents are excellent in the ability to control cholesterol distribution in vivo and have low toxicity.

IT 342026-97-5 342026-97-3 342026-61-9


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ABC expression promoters as anticholesteremics)

RN 342026-97-5 CAPLUS


CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-([4-([2-phenyl-4-oxazolyl)methoxy]phenyl)methyl)- (CA INDEX NAME)

CN 1H-Pyrazole-4-carboxylic acid, 3-([4-([2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-1-phenyl- (CA INDEX NAME)




RN 47774-55-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-([4-([2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-1-phenyl- (CA INDEX NAME)




RN 47774-56-4 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-([4-([2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-1-phenyl- (CA INDEX NAME)




RN 47774-57-5 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-([4-([2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-1-phenyl- (CA INDEX NAME)




RN 47774-58-6 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 4-([3-[2-(5-methyl-2-phenyl-4-




RN 342028-57-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-([4-([2-phenyl-4-oxazolyl)methoxy]phenyl)methyl)-3-(2-thienyl)- (CA INDEX NAME)



RN 342028-61-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-([4-([2-phenyl-4-oxazolyl)methoxy]phenyl)methyl)-3-(2-thienyl)- (CA INDEX NAME)

RE.CNT 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN

RN 2003:754366 CAPLUS Full-text

DN 137:279197

TI Preparation of five-membered heterocyclic alkanolic acid derivatives as remedies for diabetes and hyperlipidemia

IN Momose, Yu; Maekawa, Tsuyoshi; Imoto, Hiroshi; Odaka, Hiroyuki; Kimura, Hiroyuki

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002076959	A1	20021003	WO 2002-JP2741	20020322
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002339023 A1 20021009 AU 2002-239023 20020322

JP 2002348281 A 20021204 JP 2002-81631 20020322

EP 1394154 A1 20040303 EP 2002-705433 20020322

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004063775 A1 20040401 US 2003-472159 20030922


US 7241785 B2 20070710

PRA1 JP 2001-85572 A 20010323

WO 2002-392741 W 20020322

OS MARPAT 137;279197

GI




AB The title compds. I [R1 represents an optionally substituted five-membered heterocyclic group; X represents a bond, etc.; Q represents a C1-20 divalent hydrocarbon group; Y represents a bond, etc.; ring A represents an aromatic ring optionally having one to three substituents; Z represents (CH2)nZ1 (n is an integer of 0 to 8 and Z1 represents a bond, etc.), etc.; ring B represents a five-membered heterocycle optionally having one to three substituents; W represents a C1-20 divalent saturated hydrocarbon group; and R2 represents OH, etc.) are prepared. A process for preparing I is disclosed. Compds. of this invention at 0.01% in feed given to diabetic mice for 4 days caused 43% to 42% decrease of blood sugar. Formulations are given.

IT 464184-95-0P  
RL: IMP (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Preparation of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)

RN 464184-95-0 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl- (CA INDEX NAME)



IT 464184-95-0P


464184-72-1P 464184-73-4P 464184-74-5P  
464184-76-7P 464184-78-9P 464184-80-0P  
464184-85-1P 464184-89-2P 464184-90-3P  
464184-91-6P 464184-92-7P 464184-93-8P  
464184-94-9P

RL: IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)


RN 464184-61-0 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464184-62-1 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 1-methyl-3-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (CA INDEX NAME)




RN 464184-63-2 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 1-methyl-3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (CA INDEX NAME)




RN 464184-72-3 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-methyl- (CA INDEX NAME)




RN 464184-73-4 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464184-74-5 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464184-76-7 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464184-78-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-[[4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464184-87-0 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464184-88-1 CAPLUS

CN Morpholine, 4-[[3-[[4-[(2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl]methoxy]-1-phenyl-1H-pyrazol-4-yl]acetyl]- (9CI) (CA INDEX NAME)







RN 464184-89-2 CAPLUS  
CN Piperazine, 1-[[3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]-1-phenyl-1H-pyrazol-4-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 464184-90-5 CAPLUS  
CN Piperazine, 1-ethyl-4-[[3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]-1-phenyl-1H-pyrazol-4-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 464184-91-6 CAPLUS  
CN 1H-Pyrazole-5-acetic acid, 3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464184-92-7 CAPLUS  
CN 1H-Pyrazole-5-propanoic acid, 3-[[3-methoxy-4-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methoxy]-1-phenyl- (CA INDEX NAME)



RN 464184-93-8 CAPLUS  
CN 1H-Pyrazole-5-propanoic acid, 3-[[4-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464184-94-9 CAPLUS  
CN 1H-Pyrazole-5-propanoic acid, 3-[[3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methoxy]-1-phenyl- (CA INDEX NAME)




IT 464185-36-2P 464185-37-3P 464185-38-4P  
464185-39-5P 464185-55-5P 464185-56-6P  
464185-65-7P 464185-66-8P 464185-67-9P  
464185-69-1P 464185-70-4P 464185-72-6P  
464185-91-7P 464185-82-5P 464185-83-9P  
RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of five-membered heterocyclic alkanic acid derivs. as


for diabetes and hyperlipidemia)  
RN 464185-36-2 CAPLUS  
CN 1H-Pyrazole-5-carboxylic acid, 3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]-1-phenyl-, methyl ester (CA INDEX NAME)




RN 464185-37-3 CAPLUS  
CN 1H-Pyrazole-5-methanol, 3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464185-38-4 CAPLUS  
CN 1H-Pyrazole-5-carboxaldehyde, 3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464185-39-5 CAPLUS  
CN 1H-Pyrazole-5-acetonitrile, 3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]-1-phenyl- (CA INDEX NAME)




RN 464185-55-5 CAPLUS  
CN 1H-Pyrazole-4-acetic acid, 1-methyl-3-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methoxy]-, methyl ester (CA INDEX NAME)




RN 464185-56-6 CAPLUS  
CN 1H-Pyrazole-4-acetic acid, 1-methyl-3-[[4-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methoxy]-, methyl ester (CA INDEX NAME)



RN 464185-65-7 CAPLUS  
CN 1H-Pyrazole-4-acetic acid, 3-[[3-methoxy-4-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methoxy]-1-methyl-, methyl ester (CA INDEX NAME)




RN 464185-66-8 CAPLUS  
CN 1H-Pyrazole-4-acetic acid, 3-[[4-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methoxy]-1-(phenylmethyl)-, ethyl ester (CA INDEX NAME)




RN 464185-67-9 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl-, ethyl ester (CA INDEX NAME)




RN 464185-69-1 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl-, methyl ester (CA INDEX NAME)



RN 464185-70-4 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl-, methyl ester (CA INDEX NAME)




RN 464185-72-6 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-[[4-[(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl]methoxy]-1-phenyl-, ethyl ester (CA INDEX NAME)


PA Takeda Chemical Industries, Ltd., Japan  
 SC PCT Int. Appl., 375 pp.  
 CODEN: PIXKD2  
 DT Patent  
 LA English  
 FAN: CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001038325	A1	20010531	WO 2000-JP7877	20001109
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2390923	A1	20010531	CA 2000-2390923	20001109
JP 2001226350	A	20010821	JP 2000-347462	20001109
JP 3723071	B2	20051207		
BR 2000015466	A	20020806	BR 2000-15466	20001109
EP 1228067	A1	20020807	EP 2000-974857	20001109
EP 1228067	B1	20040714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002003165	A2	20030128	HU 2002-3165	20001109
JP 200317865	A	20030514	JP 2002-315096	20001109
NZ 519238	A	20031128	NZ 2000-519238	20001109
AT 271049	T	20040715	AT 2000-974857	20001109
EP 1457490	A1	20040915	EP 2004-76508	20001109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1228067	T	20041130	PT 2000-974857	20001109
ES 225252	T3	20050316	ES 2000-974857	20001109
AU 780948	B2	20050428	AU 2001-13031	20001109
RU 2252939	C2	20050527	RU 2002-115263	20001109
NO 2002002108	A	20020708	NO 2002-2108	20020502
MX 2002PA04647	A	20021031	MX 2002-PA4647	20020509
US 7179823	B1	20070220	US 2002-129702	20020509
IN 2002KN00645	A	20050311	IN 2002-KN645	20020513
ZA 2002003824	A	20031015	ZA 2002-1824	20020514
HK 1045591	A1	20041210	HK 2002-106297	20020827
JP 1999-320317	A	19991110		
JP 1999-352237	A	19991210		
JP 1999-352236	A	19991210		
EP 2000-974857	A3	20001109		
JP 2000-347462	A3	20001109		
WO 2000-JP7877	W	20001109		
OS MARPAT 135:19632				
GI				




RN 464185-81-7 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 3-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl-, ethyl ester (CA INDEX NAME)




RN 464185-82-8 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 464185-83-9 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 3-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-phenyl-, ethyl ester (CA INDEX NAME)





RE.CIT 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L1 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STN  
 CN 2001:396864 CAPLUS Full-text

DN 135:19632

TI Preparation of pyrazolyl- and pyrrolylalkanoic acid derivatives with  
 hypoglycemic and hypolipidemic activity

IN Momose, Yu, Maekawa, Tsuyoshi, Odaka, Hiroyuki, Kimura, Hiroyuki




AB Title compds. (I) [wherein R1 = (un)substituted hydrocarbon or heterocycle; X = bond, O, S, CO, CS, CR4(OR5), or NR6; R4 and R6 = independently H or (un)substituted hydrocarbon; R5 = H or hydroxyl protective group; m = 0-3; Y = O, S, SO, SO2, NR7, or NR7CO; R7 = H or (un)substituted hydrocarbon; A = (un)substituted aromatic ring; n = 1-8; B = (un)substituted N-containing 5-membered heterocycle; X1 = bond, O, S, SO, SO2, OSO2, or NR16; R16 = H or (un)substituted hydrocarbon; R2 = H or (un)substituted hydrocarbon or heterocycle; W = bond or hydrocarbon; R3 = OR8 or NR9R10; R8 = H or (un)substituted hydrocarbon; R9 and R10 = independently H or (un)substituted hydrocarbon or heterocycle; or R9 and R10 together with the N to which they are attached may form a ring] were prepared as retinoid-related receptor function regulating agents or insulin resistance improving agents. For example, Et 3-[(1-(4-hydroxybenzyl)-4-phenyl-3-pyrrolyl)propionate and 4-chloromethyl-5-methyl-2-(2-thienyl)oxazole were coupled in the presence of K2CO3 in DMF and treated with HCl to give II (77%). At a concentration of 0.001%, II reduced hypoglycemic and hypolipidemic action by 48 and 70%, resp., lowered total cholesterol by 16%, and increased the plasma anti-arteriosclerosis index by 12% compared to non-treatment groups of mice. In addition, II showed potent PPARγ-RXRα heterodimer ligand activity with EC50 of 1.5 nM. I are useful for the prevention or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, and arteriosclerosis.


IT 342023-65-8P 342023-67-0P 342023-68-1P  
 342023-69-2P 342023-70-5P 342023-72-7P  
 342023-73-8P 342023-75-0P 342023-76-1P  
 342023-75-3P 342024-06-0P 342024-07-1P  
 342025-01-8P 342025-02-5P 342025-06-3P  
 342025-07-4P 342025-10-5P 342025-11-0P  
 342025-12-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of pyrrolyl- and pyrazolylalkanoic acid derivs. as retinoid X receptor and PPAR receptor modulators)

RN 342023-65-8 CAPLUS


CN 1H-Pyrazole-4-carboxaldehyde, 3,5-dimethyl-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342023-67-0 CAPLUS  
CN 1H-Pyrazole-4-propanol, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl- (CA INDEX NAME)




RN 342023-68-1 CAPLUS  
CN Oxazole, 4-[[4-[[4-(3-iodopropyl)-3-phenyl-1H-pyrazol-1-yl]methyl]phenoxy]methyl]-5-methyl-2-phenyl- (CA INDEX NAME)




RN 342023-69-2 CAPLUS  
CN 1H-Pyrazole-4-butanenitrile, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl- (CA INDEX NAME)




RN 342023-70-5 CAPLUS  
CN Propanedioic acid, [3-[1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-1H-pyrazol-4-yl]propyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 342023-72-7 CAPLUS  
CN 1H-Pyrazole-4-methanol, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




PAGE 1-B




RN 342023-76-1 CAPLUS  
CN 1H-Pyrazole-4-carboxaldehyde, 3-[[4-[(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]-1-[[4-[(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




PAGE 1-B



RN 342023-78-3 CAPLUS  
CN 1H-Pyrazole-4-methanol, 3-(1-methylethyl)-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)



oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




PAGE 1-A



PAGE 1-B

RN 342023-73-8 CAPLUS  
CN 1H-Pyrazole-4-carboxaldehyde, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




PAGE 1-A




PAGE 1-B

RN 342023-75-0 CAPLUS  
CN 1H-Pyrazole-4-methanol, 3-[[4-[(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]-1-[[4-[(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)


RN 342024-06-0 CAPLUS  
CN 1H-Pyrazole-4-methanol, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342024-07-1 CAPLUS  
CN 1H-Pyrazole-4-carboxaldehyde, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)



RN 342025-01-8 CAPLUS  
CN 1H-Pyrazole-4-methanol, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)




RN 342025-02-9 CAPLUS  
CN 1H-Pyrazole-4-carboxaldehyde, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)



RN 342025-06-3 CAPLUS





CN 1H-Pyrazole-4-acetonitrile, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)




RN 342025-07-4 CAPLUS

CN Propanedioic acid, [[1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)-1H-pyrazol-4-yl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 342025-10-9 CAPLUS

CN 1H-Pyrazole-4-methanol, 1-[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)




RN 342025-11-0 CAPLUS

CN 1H-Pyrazole-4-carboxaldehyde, 1-[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)




RN 342025-00-7 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)-, ethyl ester (CA INDEX NAME)




RN 342026-18-0 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-(1-methylethyl)-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342026-61-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-methoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)



RN 342026-63-5 CAPLUS



CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)



RN 342026-66-8 CAPLUS

RN 342025-12-1 CAPLUS

CN Propanedioic acid, [[1-[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)-1H-pyrazol-4-yl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



IT

342023-77-2F 342024-05-2F 342025-30-2P


342026-19-3P 342026-61-3P 342026-63-5P

342026-66-8F 342026-77-1F

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


RN 342023-77-2 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-(1-methylethyl)-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, methyl ester (CA INDEX NAME)




RN 342024-05-9 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




CN 1H-Pyrazole-4-propanoic acid, 3-(1-methylethoxy)-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)



RN 342026-77-1 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)



IT

342025-85-8P 342025-86-9P 342025-87-0P

342025-88-1P 342025-90-5P 342025-93-3P

342025-94-9P 342025-95-0F 342026-00-0P

342025-03-3P 342026-04-4P 342026-56-6P

342026-08-8F 342026-09-2F 342026-10-2P

342026-11-3P 342026-12-4P 342026-14-6P

342026-15-7F 342026-16-8P 342026-19-1P

342026-20-4P 342026-21-5P 342026-23-7F

342026-25-9F 342026-26-0P 342026-27-1P

342026-35-1P 342026-36-2F 342026-48-6P

342026-49-7P 342026-50-0P 342026-51-1P

342026-52-2F 342026-53-3P 342026-54-4P

342026-55-5P 342026-56-6P 342026-58-3P

342026-59-5F 342026-60-1P 342026-62-4P

342026-64-6P 342026-65-7P 342026-67-9P

342026-68-0F 342026-69-1P 342026-70-4P

342026-74-8P 342026-76-0F 342026-78-2P

342026-79-3P 342026-80-6F 342026-83-4P

342026-84-0F 342026-85-1P 342026-86-2P

342026-87-3P 342026-88-4P 342026-96-4P

342026-97-5F 342027-06-9P 342027-15-0P

342027-16-1P 342027-17-2P 342027-18-3P

342027-19-4P 342027-20-7P 342027-21-8P

342027-22-9P 342027-23-0T 342027-32-1P

342027-33-2P 342027-34-3P 342027-79-6P

342027-80-9P 342028-43-6P 342028-42-7P

342028-44-8P 342028-45-9P 342028-46-0P

342028-47-1F 342028-55-1P 342029-56-2P

342028-57-3P 342028-61-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolyl- and pyrazolylalkanoic acid derivs. as retinoid X

receptor and PPAR receptor modulators)


RN 342025-85-8 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342025-86-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342025-87-0 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342025-88-1 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342025-90-5 CAPLUS




RN 342026-03-3 CAPLUS

CN 1H-Pyrazole-4-methanol, 1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 342026-04-4 CAPLUS

CN 1H-Pyrazole-4-butanolic acid, 1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342026-06-6 CAPLUS

CN 1H-Pyrazole-4-pentanoic acid, 1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342026-08-8 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-[4-(trifluoromethyl)phenyl]-, methyl ester (CA INDEX NAME)




CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[5-methyl-2-(4-pyridinyl)-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342025-93-8 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[2,5-dimethyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342025-94-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[2,5-dimethyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342025-95-0 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342026-00-0 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)




RN 342026-09-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-(4-fluorophenyl)-1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-10-2 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-(4-fluorophenyl)-1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)



RN 342026-11-3 CAPLUS


CN 1H-Pyrazole-4-propanoic acid, 3-(4-methoxyphenyl)-1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-12-4 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-(4-methoxyphenyl)-1-[[4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)


69 of 93

COc1cc2c(c1)nc(Cc3ccc(OCC4C(C4)C(F)(F)F)cc3)cn2CCOC(=O)CCc1c[nH]c2c1c(c[nH]2)C3=CC=C(C=C3)FFC1=CC=C(C=C1)c2nc(CCC(=O)O)n(CCN2Cc3ccc(OCC4=C(C=C5C(=C(C=C5)O)N4C)C)cc3)c6ccccc6


70 of 93

CCCC(=O)OCCc1c(CCNc2ccccc2OCc3c[nH]c4c3C#N)nn1CCCC1=C(C(=O)O)C=C(NC1Cc2ccc(OCC3=C(C)N(C(=O)O3)C4=CC=CC=C4)cc2)C5=CC=CC=C5CC1=C(C)OC(=N1)C2=CC=CC=C2OCC3=CC=CC=C3CCN4C=CC(=C4)CC(=O)O


71 of 93

CCOC(=O)CCc1cnc(Cc2ccc(Oc3cc(C)c(C#N)c3)c2)c1Cc1c(C#Cc2ccccc2)oc3ccccc13COc4ccc(cc4)CCN5C=CC(=C5)Cc6ccccc6C(=O)OCCOC(=O)CCc1c[nH]c2c1N(Cc3ccc(cc3)C(=O)NCCc4c[nH]c5c4C(=O)c6ccccc65)c2


72 of 93

Cc1c(Cc2cc(OC(=O)c3ccccc3)ccn2)oc(Cc4ccc(OCCc5ccc(OCCc6c(C)cc(C)cc6)cc5)cc4)c1Cc1c(Cc2ccccc2OCCCN3C=CC(=C3C)C(=O)O)c(O)c1c4ccccc4CCOC(=O)C=Cc1cc[nH]1Cc2ccc(OCC3=C(C)ON=C3)cc2


Double bond geometry as shown.



RN 342026-52-2 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-53-3 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342026-54-4 CAPLUS  
CN 2-Propenoic acid, 3-[3,5-dimethyl-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-1H-pyrazol-4-yl]-, ethyl ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.




RN 342026-55-5 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3,5-dimethyl-1-[[4-[[5-methyl-2-phenyl-4-




RN 342026-60-2 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 2,3-dihydro-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-3-oxo- (CA INDEX NAME)



RN 342026-62-4 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-methoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342026-64-6 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(5-methyl-2-phenyl)-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)




RN 342026-65-7 CAPLUS

oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (CA INDEX NAME)



RN 342026-56-6 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3,5-dimethyl-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




```

RN      342026-58-8   CAPLUS
CN      2-Propenoic acid, 3-[3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-1H-pyrazol-4-yl]-, ethyl ester, (2E)- (CA
INDEX NAME)


```

Double bond geometry as shown.


PAGE 1-A




PAGE 1-B




CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-propoxy- (CA INDEX NAME)




RN 342026-67-9 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-(1-methylethoxy)-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)



RN 342026-68-0 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 342026-69-1 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-3-(phenylmethoxy)- (CA INDEX NAME)



RN 342026-70-4 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[5-methyl-2-phenyl-4-

oxazolyl)methoxy]phenyl)methyl]-3-[(5-(trifluoromethyl)-2-pyridinyl)oxy]-  
(CA INDEX NAME)




RN 342026-74-8 CAPLUS


CN 2-Propenoic acid, 3-[3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl)methoxy]-1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl)methyl]-1H-pyrazol-4-yl]]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 342026-76-0 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl)methyl]-2,3-dihydro-3-oxo-, ethyl ester (CA INDEX NAME)




RN 342026-78-2 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)




RN 342026-79-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl)methyl]-3-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 342026-80-6 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]phenyl)methyl]-3-(phenylmethoxy)- (CA INDEX NAME)




RN 342026-83-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-methoxy-4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-84-0 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-methoxy-4-[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)




RN 342026-85-1 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-86-2 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 342026-87-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-methoxy-4-[[5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-88-4 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-methoxy-4-[[5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)




RN 342026-96-4 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[[2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 342026-97-5 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[[2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)




RN 342027-06-9 CAPLUS


CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl)methoxy]phenyl)methyl]- (CA INDEX NAME)




RN 342027-15-0 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342027-16-1 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[2-{4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl}ethyl]-, ethyl ester (CA INDEX NAME)




RN 342027-17-2 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[2-{4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl}ethyl]-, ethyl ester (CA INDEX NAME)




RN 342027-18-3 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342027-19-4 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342027-20-7 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342027-21-8 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342027-22-9 CAPLUS  
CN 1H-Pyrazole-4-carboxylic acid, 2,3-dihydro-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 342027-31-0 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342027-32-1 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342027-33-2 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-ethoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342027-34-3 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[3-ethoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)




RN 342027-79-6 CAPLUS  
CN 1H-Pyrazole-4-acetic acid, 3-ethoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 342027-80-9 CAPLUS  
CN 1H-Pyrazole-4-acetic acid, 3-ethoxy-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (CA INDEX NAME)



RN 342028-42-6 CAPLUS  
CN 1H-Pyrazole-4-carboxylic acid, 3-[[4-[(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl]methoxy-1-[[4-(phenoxyphenyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 342028-43-7 CAPLUS  
CN 1H-Pyrazole-4-carboxylic acid, 3-[[4-[(2-furanyl)-5-methyl-4-oxazolyl)methoxy]-3-methoxyphenyl]methoxy-1-[[4-(phenoxyphenyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 342028-44-8 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]-1-[(4-phenoxyphenyl)methyl]- (CA INDEX NAME)




RN 342028-45-9 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-[(4-phenoxyphenyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 342028-46-0 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-[(4-phenoxyphenyl)methyl]- (CA INDEX NAME)




CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)



RN 342028-61-9 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)




IT 342023-66-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrrolyl- and pyrazolylalkanoic acid derivs. as retinoid X receptor and PPAR receptor modulators)

RN 342023-64-7 CAPLUS

CN Oxazole, 4-[[4-[[3,5-dimethyl-1H-pyrazol-1-yl)methyl]phenoxy]methyl]-5-methyl-2-phenyl- (CA INDEX NAME)



IT 342023-64-9 342023-71-6 342023-74-9

342023-09-6 342023-02-1 342023-07-7

342023-13-5 342023-22-6


RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant; preparation of pyrrolyl- and pyrazolylalkanoic acid derivs. as retinoid X receptor and PPAR receptor modulators)

RN 342023-66-9 CAPLUS


CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, methyl ester (CA INDEX NAME)

RN 342028-47-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]-1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methyl]- (CA INDEX NAME)




PAGE 1-A



PAGE 1-B


RN 342028-55-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)




RN 342028-56-2 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)- (CA INDEX NAME)




RN 342028-57-3 CAPLUS



RN 342023-71-6 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




PAGE 1-A



PAGE 1-B


RN 342023-74-9 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]-1-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




PAGE 1-A


PAGE 1-B




RN 342025-09-6 CAPLUS  
CN 1H-Pyrazole-4-carboxylic acid, 1-[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 342026-02-2 CAPLUS  
CN 1H-Pyrazole-4-methanol, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-phenyl-, ethyl ester (CA INDEX NAME)



RN 342026-07-7 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-[[[trifluoromethyl]sulfonyl]oxy]-, ethyl ester (CA INDEX NAME)





RN 342026-13-5 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-3-[[[trifluoromethyl]sulfonyl]oxy]-, ethyl ester (CA INDEX NAME)

11527426-update

91 of 93


AU 771344 B2 20040318 AU 2000-60016 20000718  
US 6566376 B1 20030520 US 2000-623744 20000908  
ZA 2001010540 A 20030324 ZA 2001-10540 20011221  
WO 200200082 A 20020321 WO 2002-282 20020118  
MX 2002PA00671 A 20020702 MX 2002-PA671 20020118  
PRAI SE 1999-2765 A 19990721  
WO 2000-GB2756 W 20000718  
OS MARPAT 134:115959  
GI




AB The title compds. [I; R1, R2 = (un)substituted Ph; R3 = halo, NO2, alkyl, etc.; n = 0-3; R4 = H, OH, NR10R11; A = CO, CH2, a bond; Q = alkylene, U, W and X = (un)substituted C, N; V = (un)substituted N, O; Y = alkylene, CO; R10, R11 = H, alkyl, unsatd. alkyl, etc.; NR10R11 = (un)substituted 4-8 membered saturated azacyclic ring] and their pharmaceutically acceptable salts, useful in therapy, especially for the treatment of chemokine receptor related diseases and conditions (no data), were prepared E.g., a 2-step synthesis of 4,4-diphenylpiperidine II was given.  
IT 321404-04-0  
RL: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)  
[preparation of novel 4,4-diphenylpiperidines for the treatment of chemokine receptor related diseases and conditions]  
RN 321404-04-0 CAPLUS  
CN Piperidine, 1-[[1-[[4-chloro-2-[[3,5-dimethyl-4-isoxazolyl)methoxy]phenyl]methyl]-1H-pyrazol-3-yl]methyl]-4,4-diphenyl-, ethyl ester (CA INDEX NAME)

11527426-update

90 of 93



RN 342026-22-6 CAPLUS  
CN 1H-Pyrazole-4-propanoic acid, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-5-propyl-, ethyl ester (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2001:63991 CAPLUS Full-text  
DN 134:115959  
TI Preparation of novel 4,4-diphenylpiperidines for the treatment of chemokine receptor related diseases and conditions  
IN Baxter, Andrew John Gilby; Brough, Stephen John; McInally, Thomas  
PA AstraZeneca UK Limited, UK  
SO PCT Int. Appl., 100 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001005782	A1	20010125	WO 2000-GB2756	20000718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM				
RH: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2378084	A1	20010125	CA 2000-2378084	20000718
BR 2000012610	A	20020409	BR 2000-12610	20000718
EP 1202984	A1	20020508	EP 2000-946134	20000718
EP 1202984	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 200305383	T	20030212	JP 2001-511441	20000718
AT 233754	T	20030315	AT 2000-946134	20000718
NZ 516606	A	20030926	NZ 2000-516606	20000718

11527426-update

92 of 93




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1998:67330 CAPLUS Full-text  
DN 128:154084  
TI Preparation of aralkylazoles as tyrosine kinase inhibitors useful as antitumor agents.  
IN Momose, Yu; Matsutani, Etsuya  
PA Takeda Chemical Industries, Ltd., Japan  
SO PCT Int. Appl., 151 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9803505	A2	19980129	WO 1997-JP2479	19970717
WO 9803505	A3	19980625		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, GE, HU, IL, IS, KG, KR, KZ, LC, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RH: GH, KE, LS, MM, SD, SZ, UG, ZM, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2260999	A1	19980129	CA 1997-2260999	19970717
CA 2260999	C	20060711		
AU 9734616	A	19980210	AU 1997-34616	19970717
EP 1212562	A1	19990506	EP 1997-930819	19970717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1222653	A	19990721	CN 1997-195822	19970717
CN 1077107	B	20020102		
EP 1270571	A1	20030102	EP 2002-79001	19970717
EP 1270571	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 338754	T	20060915	AT 2002-79001	19970717
ZA 9706378	A	19990119	ZA 1997-6378	19970718
JP 11060571	A	19990302	JP 1997-193709	19970718
US 6211215	B1	20010403	US 1998-180955	19981118
CN 1349990	A	20020522	CN 2001-119519	20010518
PRAI JP 1996-191100	A	19960719		
JP 1997-155177	A	19970612		
EP 1997-930819	A3	19970717		
WO 1997-JP2479	W	19970717		



OS MARPAT 128:154084  
GI

AB Title compds. [I; R = (substituted) heteroaryl; X = O, (oxidized) S, CO, CH(OH); Y = CN, N; m = 0-10; n = 1-5; NB = (substituted) aromatic azolyl; ring containing Y is optionally further substituted], were prepared. Thus, 3-[4-[2-[(E)-phenylethenyl]-4-oxazolyloxy]phenyl]propyl methanesulfonate (preparation given) was added to a mixture of imidazole and NaH in DMF followed by stirring for 1.5 h at 70° to give 4-[4-[3-(1-imidazolyl)propyl]phenoxy]methyl]-2-[(E)-2-phenylethenyl]oxazole. The latter inhibited proliferation of MDA-MB-453 human breast cancer cells with IC<sub>50</sub> = 0.25 nM.


IT 202592-65-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of aralkylazoles as tyrosine kinase inhibitors useful as anticancer agents)

RN 202592-65-2 CAPLUS

CN Oxazole, 2-[2-phenylethenyl]-4-[[4-[3-(1H-pyrazol-1-yl)propyl]phenoxy]methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



\*&gt; log hold

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

82.35 274.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-12.48 -12.48

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:04:10 ON 11 DEC 2007